Phaseline

Companies › ONL Therapeutics

ONL Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Nov 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ONL1204 Ophthalmic Solution
Fragment apoptosis stimulator (FAS) receptor inhibitor
FASPhase 2Geographic Atrophy (GA)Nov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06659445ONL1204 Ophthalmic SolutionPhase 2Geographic Atrophy (GA)OphthalmologyNov 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

FAS (1)

Companies with the same targets

–

Companies built like this

Qlaris Bio Aperta Biosciences Jiangsu Jingze Biopharmaceutical BioTheraVision Vantage Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.